ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint744,816 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentZugSarepta International Holdings GmbH
Sarepta International Holdings GmbH Logo
Verified· 2 sources

Sarepta International Holdings GmbH

Summary

About the company

The core activity of Sarepta Therapeutics is the development and manufacturing of gene therapies for the treatment of rare diseases, particularly muscular dystrophies such as Duchenne muscular dystrophy, limb-girdle muscular dystrophy (LGMD), and Charcot-Marie-Tooth disease. The company focuses on researching and developing precision gene medicine and aims to increase efficiency in drug development and shorten the time from laboratory to patient.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered8
Precision genetic medicine for rare diseases
Precision genetic medicine for rare diseases, developed through Gene Therapy, RNA technologies and Gene Editing; focus on neuromuscular and other rare genetic disorders.
Gene therapy development
Gene therapy development to supplement missing or faulty genes; includes the Gene Therapy Engine and the development of therapies for rare genetic disorders.
RNA technologies
RNA technologies using an Exon-Skipping approach for the treatment of genetic disorders; part of the Precision-Genetic-Medicine platform and focused on rare diseases.
Gene editing
Gene editing to remove or cut out mutated exons, including with CRISPR/Cas9; part of the development work for rare genetic diseases.
Clinical studies
Clinical studies for investigational therapies in various stages of development; carefully designed and conducted to develop treatments for rare diseases.

Knowledge

No knowledge articles yet

Once Sarepta International Holdings GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Sarepta International Holdings GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Sarepta International Holdings GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Sarepta International Holdings GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Baarerstrasse 14
6300 Zug

At a glance

Legal form
Limited Liability Company
UID
CHE-319.605.632
Founded
2017 · 9 years
Last commercial register change
October 17, 2023
Employees
1 to 10

Similar companies

JP
Jazz Pharmaceuticals Switzerland GmbH
Zug
MB
MOHE BioTech (Suisse) SA
Zug
OT
Olympic Therapeutics AG
Zug
OT
Orchard Therapeutics (Switzerland) GmbH
Zug
PB
Packgene Biotech AG
Zug
AA
ACROBiosystems AG
Zug
CP
Crinetics Pharmaceuticals Europe GmbH
Zug
NT
Nektar Therapeutics Europe GmbH
Zug